Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan

Lee, Hsin Yi; Hung, Mei; Hu, Fang; Chang, Yu Yin; Hsieh, Ching-Lin; Wang, Jung‐Der

doi:10.1016/j.jfma.2012.12.015

Cited by 75 publications

(56 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To minimize collinearity, repeated measurements were performed more than 2 weeks apart. Using the EQ-5D scoring function from Taiwan [19], we transformed the health state parameters into a utility value ranging from 0 to 1, where 0 represents death and 1 indicates full health. To present the utility value for each group, we constructed linear mixed models to consider random effects from subjects because EQ-5Ds were repeatedly measured.…”

Section: Quality Of Lifementioning

confidence: 99%

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan

et al. 2020

Self Cite

View full text Add to dashboard Cite

IntroductionComparison of the effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors (TKIs) would improve patients' clinical benefits and save costs. Using realworld data, this study attempted to directly compare the effectiveness and cost-effectiveness of first-line afatinib, erlotinib, and gefitinib. MethodsDuring May 2011-December 2017, all patients with non-small cell lung cancer (NSCLC) visiting a tertiary center were invited to fill out the EuroQol five-dimension (EQ-5D) questionnaires and World Health Organization Quality of Life, brief version (WHOQOL-BREF), and received follow-ups for survival and direct medical costs. A total of 379 patients with EGFR mutation-positive advanced NSCLC under first-line TKIs were enrolled for analysis. After propensity score matching for the patients receiving afatinib (n = 48), erlotinib (n = 48), and gefitinib (n = 96), we conducted the study from the payers' perspective with a lifelong time horizon. ResultsPatients receiving afatinib had the worst lifetime psychometric scores, whereas the differences in quality-adjusted life expectancy (QALE) were modest. Considering 3 treatments together, afatinib was dominated by erlotinib. Erlotinib had an incremental cost-effectiveness of US$17,960/life year and US$12,782/QALY compared with gefitinib. Acceptability curves showed that erlotinib had 58.6% and 78.9% probabilities of being cost-effective given a threshold of 1 Taiwanese per capita GDP per life year and QALY, respectively.

show abstract

Section: Quality Of Lifementioning

confidence: 99%

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is despite the availability of EQ‐5D (the most commonly used generic, preference‐based measure of health‐related quality of life) value sets for a number of APAC countries . Only recently have most of the EQ‐5D value sets been developed, so moving forward, it may be increasingly practical to estimate QALYs within the region. However, it is likely that a number of APAC countries (eg, Nepal, Cambodia, and Vietnam) will not have the resources available to calculate QALYs specifically for their country and will have to rely on utility weights from other countries.…”

Section: The Frameworkmentioning

confidence: 99%

Beyond cost‐effectiveness: A five‐step framework for appraising the value of health technologies in Asia‐Pacific

Finkelstein

Krishnan

Doble

2019

Health Planning & Management

View full text Add to dashboard Cite

Summary Given resource constraints and the potential for increasingly high‐cost, cost‐effective medicines to become available, policymakers require strategies that go beyond cost‐effectiveness when making resource allocation decisions. This manuscript presents a five‐step framework that complements traditional health technology assessment (HTA) guidance documents that policymakers in Asia‐Pacific and elsewhere may consider when setting up HTA guidelines and/or evaluating whether or not to subsidize a medicine or other health innovations. The framework recommends that subsidy decisions be based on five criteria: the relative burden of the condition as compared with other conditions (step 1), comparative and cost‐effectiveness of the medicine (steps 2 and 3), the short‐term impact on the budget (step 4), and other considerations including patient and societal preferences (step 5). Our approach, which is a complement to traditional HTA guidance documents, is not prescriptive but provides an evidence‐based framework that HTA agencies in Asia‐Pacific can follow as they aim to deliver value‐based medicines to their constituents.

show abstract

“…The EQ-5D has recently been shown to have good validity and moderate reliability in Taiwanese populations [18]. We applied the value systems of the Taiwan version using the time trade-off method [19].…”

Section: Eq-5d Health-related Quality Of Life Questionnairementioning

confidence: 99%

Validation of the EQ-5D in Patients with Traumatic Limb Injury

Hung

Chen

et al. 2014

J Occup Rehabil

Self Cite

View full text Add to dashboard Cite

show abstract

Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan

Abstract: This study reaffirms the differences in health-related preference values across countries. The high proportion of negative values might indicate that we have also partially measured the intensity of fear in addition to the utility of different health states.

Cited by 75 publications

References 12 publications

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan

Beyond cost‐effectiveness: A five‐step framework for appraising the value of health technologies in Asia‐Pacific

Validation of the EQ-5D in Patients with Traumatic Limb Injury

Contact Info

Product

Resources

About